Gesynta Pharma AB Revenue and Competitors
Estimated Revenue & Valuation
- Gesynta Pharma AB's estimated annual revenue is currently $3.8M per year.
- Gesynta Pharma AB's estimated revenue per employee is $201,000
- Gesynta Pharma AB's total funding is $58M.
Employee Data
- Gesynta Pharma AB has 19 Employees.
- Gesynta Pharma AB grew their employee count by 6% last year.
Gesynta Pharma AB's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | VP Clinical R&D | Reveal Email/Phone |
4 | Pre-Clinical Project Manager | Reveal Email/Phone |
5 | Clinical Project Leader | Reveal Email/Phone |
6 | Consultant CMC | Reveal Email/Phone |
Gesynta Pharma AB Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15.1M | 75 | -12% | N/A | N/A |
#2 | $120.6M | 600 | 22% | N/A | N/A |
#3 | $27.7M | 138 | -67% | N/A | N/A |
#4 | $31.2M | 155 | 14% | N/A | N/A |
#5 | $25.3M | 126 | 29% | N/A | N/A |
#6 | $124.8M | 621 | 5% | N/A | N/A |
#7 | $11.3M | 56 | 19% | N/A | N/A |
#8 | $3M | 15 | -17% | N/A | N/A |
#9 | $34M | 169 | 27% | N/A | N/A |
#10 | $4.8M | 24 | -4% | N/A | N/A |
What Is Gesynta Pharma AB?
Gesynta Pharma's drug candidate vipoglanstat (GS-248) is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life, and current drug treatments are inadequate for many patients. \n\nGesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy.\n\nGesynta Pharma’s second drug candidate to reach clinical development, GS-073, has the same mode of action as vipoglanstat. GS-073 is ready to enter clinical phase I for the treatment of chronic inflammatory pain.\n\nGesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.
keywords:N/A
$58M
Total Funding
19
Number of Employees
$3.8M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Stockholm
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.7M | 19 | -24% | N/A |
#2 | N/A | 19 | -42% | N/A |
#3 | $2M | 20 | -44% | N/A |
#4 | $5M | 20 | -41% | N/A |
#5 | $2M | 20 | -23% | N/A |